Satoshi Takahashi

Prof. Satoshi Takahashi


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
STSatoshi Takahashi
Satoshi Takahashi
RHRyoichi Hamasuna
Ryoichi Hamasuna
MYMitsuru Yasuda
Mitsuru Yasuda
SASoichi Arakawa
Soichi Arakawa
KTKazushi Tanaka
Kazushi Tanaka
HKHiroshi Kiyota
Hiroshi Kiyota

1 January 2013 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
PDF file
STSatoshi Takahashi
Satoshi Takahashi
TMTetsuro Matsumoto
Tetsuro Matsumoto
RHRyoichi Hamasuna
Ryoichi Hamasuna
MYMitsuru Yasuda
Mitsuru Yasuda
SIShin Ito
Shin Ito
SFSouichirou Fukuda
Souichirou Fukuda

1 January 2011 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
PDF file
STSatoshi Takahashi
Satoshi Takahashi
KIKohji Ichihara
Kohji Ichihara
JHJiro Hashimoto
Jiro Hashimoto
YKYuichiro Kurimura
Yuichiro Kurimura
TTTaiji Tsukamoto
Taiji Tsukamoto
TSTakashi Satoh
Takashi Satoh

27 December 2019 in BMC Urology
Verified
Journal Article
Open access
PDF file
JMJun Miyazaki
Jun Miyazaki
MOMizuki Onozawa
Mizuki Onozawa
STSatoshi Takahashi
Satoshi Takahashi
YMYuka Maekawa
Yuka Maekawa
MYMitsuru Yasuda
Mitsuru Yasuda
SYShingo Yamamoto
Shingo Yamamoto
Background: To study the outcomes and experiences of using metallic stents in treating patients with malignant ureteral obstruction (MUO), we examined the effects of metallic ureteral stenting using the Cook Resonance® stent in the treatment of MUO. Methods: All patients who had a Resonance metallic stent inserted between April 2015 and March 2018 at one of multiple facilities were prospectively observed with a 1-year follow-up. The primary outcome was the patency rate of the metallic ureteral stent. The secondary outcomes included the complications (e.g., infection and fever). Results: Although stent insertion was attempted in 50 patients, the stent could not be inserted as a ureteral stent in three patients due to severe ureteral stricture, and one ureteral cancer patient was excluded from the analysis. The remaining 46 patients’ median age was 67 years (range 28–85 years) (16 males, 30 females). Twenty-four patients died during the study; their median survival time was 226 days. The median follow-up period for the censored patients was 355 days (range 16–372 days), and just seven patients were still alive without Resonance failure > 1 year later. The women’s IPSS scores tended to be lower than those of the men. Regarding the OABSS score, although the women’s total score tended to be low, the difference between the men’s and women’s scores was nonsignificant. The bacteria detected from urine culture after stent insertion were more gram-positive than gram-negative. Conclusion: Metallic ureteric stenting using the Resonance stent is safe and effective for treating MUO. Subjective symptoms were relatively less in the female patients.

1 January 2006 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
STSatoshi Takahashi
Satoshi Takahashi
KTKoh Takeyama
Koh Takeyama
SMShintaro Miyamoto
Shintaro Miyamoto
KIKohji Ichihara
Kohji Ichihara
TMToshihiro Maeda
Toshihiro Maeda
TTTaiji Tsukamoto
Taiji Tsukamoto

1 June 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RKRyo Kobayashi
Ryo Kobayashi
RMRyosei Murai
Ryosei Murai
KAKoichi Asanuma
Koichi Asanuma
YFYoshihiro Fujiya
Yoshihiro Fujiya
STSatoshi Takahashi
Satoshi Takahashi